In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in ...

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

In PAH, 5-year mortality is similar with and without obesity, even though patients with obesity have more comorbidities and worse functional capacity.

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and ...

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Keros Therapeutics (NASDAQ:KROS) discontinues a hypertension drug trial, cuts workforce by 45%, and faces shareholder ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

A Hundred Experts Urge Strengthening Early Diagnosis of Pulmonary Hypertension in Latin America ...